Cargando…
Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study
BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitor (ICI)-associated myocarditis is a fatal immune-related adverse events (irAEs), which is prone to affecting multiple organ systems. Multi-organ irAEs have not been fully studied in ICI-associated myocarditis. Therefore, we aimed to explore the imp...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340212/ https://www.ncbi.nlm.nih.gov/pubmed/35924238 http://dx.doi.org/10.3389/fimmu.2022.879900 |
_version_ | 1784760351786532864 |
---|---|
author | Xie, Xiaohong Wang, Liqiang Li, Yingqing Xu, Yan Wu, Jianhui Lin, Xinqing Lin, Wen Mai, Qicong Chen, Zhanhong Zhang, Jiexia Xie, Zhanhong Qin, Yinyin Liu, Ming Lu, Mingjun Luo, Bihui Zhou, Chengzhi |
author_facet | Xie, Xiaohong Wang, Liqiang Li, Yingqing Xu, Yan Wu, Jianhui Lin, Xinqing Lin, Wen Mai, Qicong Chen, Zhanhong Zhang, Jiexia Xie, Zhanhong Qin, Yinyin Liu, Ming Lu, Mingjun Luo, Bihui Zhou, Chengzhi |
author_sort | Xie, Xiaohong |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitor (ICI)-associated myocarditis is a fatal immune-related adverse events (irAEs), which is prone to affecting multiple organ systems. Multi-organ irAEs have not been fully studied in ICI-associated myocarditis. Therefore, we aimed to explore the impact of multi-organ irAEs on ICI myocarditis in terms of clinical features, treatment, and prognosis. METHODS: This was a retrospective study. The clinical data of ICI myocarditis patients were collected from 6 hospitals in China. The risk factors and characteristics of pure myocarditis and multi-organ irAEs were analyzed. The overall survival (OS) after myocarditis was analyzed and univariate and multivariate regression analysis were performed. RESULTS: A total of 46 patients were analyzed in this study. Multi-organ irAEs were common (30/46, 65.2%) and prone to severe heart failure. The severe myocarditis was observed in 32 patients (69.6%). When myocarditis occurred, neutrophil to lymphocyte ratio, C-reactive protein, lactate dehydrogenase, interleukin (IL)-6, IL-10, creatine kinase, MB isoenzyme of creatine kinase, and brain natriuretic peptide increased from baseline, but absolute lymphocyte count decreased. Thymoma (B2/B3) was a risk factor for multi-organ irAEs. Heart failure and myocarditis were more severe in patients with multi-organ irAEs and require early corticosteroid therapy (<24 hours). Univariate analysis showed that age ≥ 60 years, myocarditis (grade 3-4), heart failure (grade 3-4), multi-organ irAEs, and severe myocarditis were associated with OS after myocarditis. After adjusting for other factors, heart failure (grade 3-4) was an independent risk factor for immune-related myocarditis (HR: 6.655, 95% CI: 1.539-28.770, p=0.011). CONCLUSION: Patients with ICI-associated myocarditis had multi-organ irAEs with a high incidence of severe myocarditis, mortality, and poor prognosis. Thymoma was prone to those patients with multiple organs involvement. Patients could benefit from early corticosteroid intervention. Heart failure (grade 3-4) was an independent risk factor for OS after myocarditis. |
format | Online Article Text |
id | pubmed-9340212 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93402122022-08-02 Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study Xie, Xiaohong Wang, Liqiang Li, Yingqing Xu, Yan Wu, Jianhui Lin, Xinqing Lin, Wen Mai, Qicong Chen, Zhanhong Zhang, Jiexia Xie, Zhanhong Qin, Yinyin Liu, Ming Lu, Mingjun Luo, Bihui Zhou, Chengzhi Front Immunol Immunology BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitor (ICI)-associated myocarditis is a fatal immune-related adverse events (irAEs), which is prone to affecting multiple organ systems. Multi-organ irAEs have not been fully studied in ICI-associated myocarditis. Therefore, we aimed to explore the impact of multi-organ irAEs on ICI myocarditis in terms of clinical features, treatment, and prognosis. METHODS: This was a retrospective study. The clinical data of ICI myocarditis patients were collected from 6 hospitals in China. The risk factors and characteristics of pure myocarditis and multi-organ irAEs were analyzed. The overall survival (OS) after myocarditis was analyzed and univariate and multivariate regression analysis were performed. RESULTS: A total of 46 patients were analyzed in this study. Multi-organ irAEs were common (30/46, 65.2%) and prone to severe heart failure. The severe myocarditis was observed in 32 patients (69.6%). When myocarditis occurred, neutrophil to lymphocyte ratio, C-reactive protein, lactate dehydrogenase, interleukin (IL)-6, IL-10, creatine kinase, MB isoenzyme of creatine kinase, and brain natriuretic peptide increased from baseline, but absolute lymphocyte count decreased. Thymoma (B2/B3) was a risk factor for multi-organ irAEs. Heart failure and myocarditis were more severe in patients with multi-organ irAEs and require early corticosteroid therapy (<24 hours). Univariate analysis showed that age ≥ 60 years, myocarditis (grade 3-4), heart failure (grade 3-4), multi-organ irAEs, and severe myocarditis were associated with OS after myocarditis. After adjusting for other factors, heart failure (grade 3-4) was an independent risk factor for immune-related myocarditis (HR: 6.655, 95% CI: 1.539-28.770, p=0.011). CONCLUSION: Patients with ICI-associated myocarditis had multi-organ irAEs with a high incidence of severe myocarditis, mortality, and poor prognosis. Thymoma was prone to those patients with multiple organs involvement. Patients could benefit from early corticosteroid intervention. Heart failure (grade 3-4) was an independent risk factor for OS after myocarditis. Frontiers Media S.A. 2022-07-18 /pmc/articles/PMC9340212/ /pubmed/35924238 http://dx.doi.org/10.3389/fimmu.2022.879900 Text en Copyright © 2022 Xie, Wang, Li, Xu, Wu, Lin, Lin, Mai, Chen, Zhang, Xie, Qin, Liu, Lu, Luo and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Xie, Xiaohong Wang, Liqiang Li, Yingqing Xu, Yan Wu, Jianhui Lin, Xinqing Lin, Wen Mai, Qicong Chen, Zhanhong Zhang, Jiexia Xie, Zhanhong Qin, Yinyin Liu, Ming Lu, Mingjun Luo, Bihui Zhou, Chengzhi Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study |
title | Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study |
title_full | Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study |
title_fullStr | Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study |
title_full_unstemmed | Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study |
title_short | Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study |
title_sort | multi-organ immune-related adverse event is a risk factor of immune checkpoint inhibitor-associated myocarditis in cancer patients: a multi-center study |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340212/ https://www.ncbi.nlm.nih.gov/pubmed/35924238 http://dx.doi.org/10.3389/fimmu.2022.879900 |
work_keys_str_mv | AT xiexiaohong multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy AT wangliqiang multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy AT liyingqing multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy AT xuyan multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy AT wujianhui multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy AT linxinqing multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy AT linwen multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy AT maiqicong multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy AT chenzhanhong multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy AT zhangjiexia multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy AT xiezhanhong multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy AT qinyinyin multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy AT liuming multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy AT lumingjun multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy AT luobihui multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy AT zhouchengzhi multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy |